This was a stressful week for healthcare. In Mexico, consumer associations denounced soda, alcohol and junk food manufacturers for blocking regulations to reduce the sale of said products and Mexicans were warned not to buy medicines online. Moreover, new Ebola cases are being reported in Africa and Novartis continues dealing with the fallout of its decision to hire Michael Cohen’s firm.
In better news, creators of gene-editing CRISPR launched a new company, two French pharmaceuticals merged into one and Eli Lilly looks toward expanding its oncology portfolio. Furthermore, Mexico received 1 million Hepatitis B vaccines putting an end to a shortage that began last year, when the last shipment was rejected by COFEPRIS due to poor quality.
MHR asked Jose Alberto Peña, Director General of Grupo Marzan, what e-commerce can do for traditional logistic companies. Read his answer here.
The Ministry of Health warned citizens against buying medication online, stating that about 9 in 10 medicines might be altered.
The associations Consumer’s Power, SaludHable and the Action Center against Alcoholism slammed manufacturers of soda, junk food, alcohol and tobacco for stopping regulations to control their sale. According to the association, these four products are responsible for 77 percent of deaths in Mexico.
The Ebola crisis detected last week is far form over, with 23 deaths in the DRC. Furthermore, a new case in the country led the WHO to fear an epidemic.
Eli Lilly wants to buy AurKa Pharma, developer of cancer treatments for solid tumors, for US$576 million.
Novartis is still in the spotlight, with US Senator Ron Wyden opening an investigation into the US$1.2 million paid to Essential Consultants, a company belonging to Michael Cohen, President Trump’s attorney in a cash-for-access scandal. On Wednesday, Novartis’ top lawyer apologized for the payments and stepped down.
Creators of gene-editing technology CRISPR launch new company, Beam Therapeutics, to create precision genetic medicines that edit “individual base pairs in the genetic code.”
French pharmaceuticals Vectalys and FlashCell merge into Flash Therapeutics. The newly-created company will develop lentiviral vectors, a method to transport and insert a vector into an organism to modify a gene using lentiviruses.